Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Martin H. Voss et al.|Nature Genetics|2019Cited by 4.4k
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Nikolaus Schultz, Jianjiong Gao et al.|JCO Precision Oncology|2017Cited by 2.7k
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell CarcinomaSean M. McBride, Nancy Y. Lee, Eric J. Sherman et al.|Journal of Clinical Oncology|2020Cited by 393
Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCRXinran Ma, Shrujal S. Baxi|medRxiv|2020Cited by 357
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAmanda Psyrri, Tanguy Y. Seiwert, Jérôme Fayette et al.|Annals of Oncology|2022Cited by 144